Zobrazeno 1 - 10
of 14
pro vyhledávání: '"R. E Mendes"'
Autor:
Dmitriy M. Martirosov, Monique R. Bidell, Manjunath P. Pai, Marc H. Scheetz, Susan L. Rosenkranz, Corey Faragon, M. Malik, R. E. Mendes, R. N. Jones, Louise-Anne McNutt, Thomas P. Lodise
Publikováno v:
BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-7 (2017)
Abstract Background In vitro data suggests that suboptimal initial vancomycin exposure may select for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infections. However, no clinical studies have evaluated the relationship between
Externí odkaz:
https://doaj.org/article/f084be5c41784487b40cdab60246cae4
Publikováno v:
TP94. TP094 DISCOVERIES IN BACTERIAL AND VIRAL PNEUMONIA PATHOGENESIS.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca69c80437e38e924e90669800b6e1ed
https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3890
https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3890
Autor:
M Jurkovic, Kevin A. Meyer, Eric Wenzler, Zackery P Bulman, A Vialichka, D Lamm, R E Mendes, Mark Biagi, Shree Patel
Publikováno v:
Antimicrob Agents Chemother
The intrinsic L1 metallo- and L2 serine-β-lactamases in Stenotrophomonas maltophilia make it naturally multidrug resistant and difficult to treat. There is a need to identify novel treatment strategies for this pathogen, especially against isolates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::226ace1f427ff512c6987331483e057b
https://europepmc.org/articles/PMC7674038/
https://europepmc.org/articles/PMC7674038/
Autor:
A Shajee, R E Mendes, Shree Patel, Eric Wenzler, Mark Biagi, Myung Gull Lee, M Jurkovic, Tiffany Wu, A Vialichka
Publikováno v:
Antimicrobial Agents and Chemotherapy
The production of an L1 metallo-β-lactamase and an L2 serine active-site β-lactamase precludes the use of β-lactams for the treatment of Stenotrophomonas maltophilia infections. Preclinical data suggest that cefiderocol is the first approved β-la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8627898192ac0850135ca4ef1ec718e
http://europepmc.org/articles/PMC7449157
http://europepmc.org/articles/PMC7449157
Autor:
Matthew Finnemeyer, Susan L. Rosenkranz, Susan C Bleasdale, Eric Wenzler, K M Meyer, Larry H. Danziger, Kristen L. Bunnell, Keith A. Rodvold, R E Mendes, Monica K. Sikka
Publikováno v:
Antimicrob Agents Chemother
The ex vivo bactericidal activity and pharmacodynamics of fosfomycin in urine were evaluated in 18 healthy subjects. Subjects received 3 g every other day (QOD) for 3 doses and then every day (QD) for 7 doses or vice versa. Serial urine samples were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9006c6c72048f8e584f34236acd6cd5
https://doi.org/10.1128/aac.02102-19
https://doi.org/10.1128/aac.02102-19
Autor:
Eric Wenzler, A Vialichka, Xing Tan, R E Mendes, Kevin A. Meyer, Tiffany Wu, M Jurkovic, Mark Biagi
Publikováno v:
J Clin Microbiol
Stenotrophomonas maltophilia is difficult to treat due to the production of multiple intrinsic and acquired mechanisms of resistance. Trimethoprim-sulfamethoxazole (TMP-SMZ) and the fluoroquinolones have traditionally been considered the drugs of cho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8f1e33ddf3bd9aabde2bb3715ce0b9e
https://pubmed.ncbi.nlm.nih.gov/31748318
https://pubmed.ncbi.nlm.nih.gov/31748318
Publikováno v:
Journal of the Pediatric Infectious Diseases Society. 10:S5-S5
Background Ceftazidime–avibactam is US FDA approved for the treatment of pneumonia and complicated intra-abdominal and urinary tract infections in adults, and it is in late-stage clinical development for the treatment of pediatric patients. Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fef9db8f687898f0e785e13ce306ac3b
https://doi.org/10.1093/jpids/piaa170.015
https://doi.org/10.1093/jpids/piaa170.015
Autor:
Louise-Anne McNutt, Ronald N. Jones, Dmitriy M. Martirosov, Marc H. Scheetz, Thomas P. Lodise, Manjunath P. Pai, Monique R. Bidell, Corey Faragon, Susan L. Rosenkranz, Meenakshi Malik, R. E. Mendes
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-7 (2017)
BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-7 (2017)
Background In vitro data suggests that suboptimal initial vancomycin exposure may select for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infections. However, no clinical studies have evaluated the relationship between initial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bac57133d0703c56464bee35a6d61d05
https://doi.org/10.1186/s12879-017-2609-0
https://doi.org/10.1186/s12879-017-2609-0
Autor:
Dee Shortridge, R. E. Mendes, M Castanheira, Michael A. Pfaller, H.S. Sader, Leonard R. Duncan, R. K. Flamm
Publikováno v:
Journal of Infectious Diseases and Treatment.
Telavancin had MIC50, MIC90, and MIC100 values of 0.03, 0.06, and 0.12 μg/mL, respectively, against methicillinsusceptible (MSSA), methicillin-resistant (MRSA), and MRSA multidrug-resistant (MDR) subsets of Staphylococcus aureus. Isolates with eleva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a0c8799054fc34975fc636bf7e6ad6b
https://doi.org/10.21767/2472-1093.100038
https://doi.org/10.21767/2472-1093.100038
Publikováno v:
European Journal of Clinical Microbiology & Infectious Diseases
The efficacy and safety of telavancin is under evaluation for the treatment of subjects with complicated Staphylococcus aureus bacteremia and S. aureus right-sided infective endocarditis. This study evaluated the telavancin activity against a global
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be775d790dfbb563309e3fe990cd6ae9
https://pubmed.ncbi.nlm.nih.gov/28111724
https://pubmed.ncbi.nlm.nih.gov/28111724